Abbott Laboratories stock at EUR 90.33, USD 174.3 billion value
Published on 10/12/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Abbott Laboratories stock was at EUR 90.33 at Lang & Schwarz on October 12, 2026, up EUR 1.47 or 1.65 percent versus the October 9 Xetra close.
- Market capitalization was USD 174.3 billion, with a P/E ratio of 32.40 and a dividend yield of 2.00 percent.
- Second-quarter 2026 revenue reached USD 12.59 billion, up 13.00 percent year over year.
- Third-quarter 2026 results are scheduled for October 21, 2026, before the US market opens.
Abbott Laboratories (ISIN US0028241000) was trading at EUR 90.33 at Lang & Schwarz on October 12, 2026 at 4:48 p.m. CEST, up EUR 1.47 or 1.65 percent versus the October 9 Xetra close of EUR 88.86. Its market capitalization was USD 174.3 billion on October 12, 2026.
Price moves within the range
The Lang & Schwarz bid was EUR 90.22 and the ask was EUR 90.44 at 4:48 p.m. CEST. Abbott Laboratories stock remains between its 52-week low of USD 81.97 and high of USD 133.34, based on the October 12, 2026 primary-market quote.
The current valuation gives the price report a clear second dimension. The P/E ratio was 32.40 and the trailing dividend yield was 2.00 percent on October 12, 2026, while the latest quote volume was 1,223,058 shares against an average volume of 9,645,167.
Second-quarter figures set the baseline
According to Ticker Scout on July 16, 2026, Abbott reported USD 12.59 billion in second-quarter 2026 net sales, up 13.00 percent on a reported basis, alongside GAAP diluted earnings per share of USD 0.53 and adjusted diluted earnings per share of USD 1.31. The company raised full-year 2026 adjusted diluted earnings per share guidance to USD 5.45-5.60 from USD 5.38-5.58.
Markets Insider reported on October 7, 2026 that Barclays analyst Matt Miksic maintained a Buy rating and set a USD 120.00 price target. That target is a separate US-dollar reference and is not combined with the euro quotation.
Comparison with peers
Abbott Laboratories (Lang & Schwarz, EUR): plus 1.65 percent, P/E 32.40, market capitalization USD 174.3 billion
Medtronic (NYSE, USD): plus 3.07 percent, P/E 22.45, market capitalization USD 116.7 billion
Boston Scientific Corporation (NYSE, USD): plus 0.67 percent, P/E 17.52, market capitalization USD 63.9 billion
Next scheduled reporting date
According to FT on September 30, 2026, Abbott will announce third-quarter 2026 results on October 21, 2026, before the market opens. The earnings date gives the current quotation a defined upcoming reference point.
Stock price and market context
Abbott Laboratories stock was trading at EUR 90.33 at Lang & Schwarz on October 12, 2026 at 4:48 p.m. CEST, up 1.65 percent versus the October 9 Xetra close of EUR 88.86. The primary listing is NYSE in USD, while the German investor reference remains the euro quotation.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories market snapshot
- Company: Abbott Laboratories
- ISIN: US0028241000
- WKN: 850103
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 12, 2026, 4:48 p.m. CEST): EUR 90.33
- Change versus Xetra close: plus 1.65 percent
- Xetra close (October 9, 2026): EUR 88.86
- Market capitalization: USD 174.3 billion (as of October 12, 2026)
- 52-week range: USD 81.97-133.34 (as of October 12, 2026)
- Sector / Industry: Healthcare / Medical devices
- Index membership: S&P 500
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
